All the news Showing 10 of 141 articles from: Nucleotide Ns5B polymerase inhibitorsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir safe and effective for genotype 1 HCV Liz Highleyman / 22 October 2014 A single-tablet regimen containing the hepatitis C virus (HCV) nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor ledipasvir – the combination in Gilead Science's recently approved Harvoni pill – was well-tolerated and cured 97% of patients with HCV genotype 1 in the Phase 3 ION trials, ... After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients Medscape (requires registration) / 29 September 2014 European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults Gilead press release / 29 September 2014 As Gilead Mulls Price of Next Hepatitis C Drug, Top Activist Refutes "Bogus" Math TheBody.com / 24 September 2014 The new $84,000 hepatitis C treatment is losing momentum, for now Washington Post / 22 September 2014 Gilead’s Proposed Hepatitis C Medicines License: How Badly Will it Miss the Target? Infojustice / 17 September 2014 Access to sofosbuvir in middle-income countries I-MAK / 17 September 2014 AbbVie 3D hepatitis C regimen is well-tolerated in Phase 3 trials HIVandHepatitis.com / 15 September 2014 Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C Fierce PharmaMarketing / 11 September 2014 Sofosbuvir + ribavirin cures hepatitis C for more than 80% of people with HIV and HCV co-infection Liz Highleyman / 28 July 2014 An interferon-free regimen of sofosbuvir (Sovaldi) plus ribavirin for 24 weeks led to sustained hepatitis C virological response in 84 to 89% of HIV-positive people with chronic hepatitis C genotypes 1, 2, ... ← Prev1...23456...15Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive